We’re joined by David McDermott, MD, and Meredith Regan, ScD to discuss some of the upcoming RCC presentations at ASCO 2023, as well as how to best interpret KM curves and comparative analysis. Dr. McDermott is a professor of medicine at Harvard Medical School and a physician at Beth Israel Deaconess Medical Center. Dr. Regan is an associate professor of medicine at Dana-Farber Cancer Institute. ...
The Uromigos
The Uromigos, Thomas Powles, MD, and Brian Rini, MD, FASCO, highlight the latest developments in genitourinary cancers. Each podcast episode features a guest expert from around the world discussing the latest data, debates, and manuscripts relevant to the practical clinical care of GU oncology patients.
Latest Episode
Advertisement
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
Professor Nick James discusses the success of the STAMPEDE trial on the use of abiraterone in patients with prostate cancer.
Dr. Meeks discusses expression-based subtypes for defining pathologic response to neoadjuvant ICIs in patients with MIBC.
We discuss new data in bladder cancer and more presented at the 2023 American Urological Association Annual Meeting.
An ODAC meeting determined that olaparib plus abiraterone for mCRPC should be restricted to patients with BRCA mutations.
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
Advertisement
The Uromigos: Live & Unplugged 2022
The Uromigos: Live & Unplugged event incorporated presentations and discussions in the field of urologic malignancies.
Cancer patient Michael Whitley explains how The Uromigos help him understand new prostate cancer treatments and research.
Matthew Tucker, MD from Grandview Cancer Center talks about why he enjoys The Uromigos and what his favorite episodes are.
Chandler Park, MD from University of Louisville Hospital talks about why he recommends The Uromigos podcast.
Kidney Cancer Discussions
Dr. Daniel Heng joins us to discuss IMDC classification for RCC and the treatment of patients with favorable risk disease.
Toni Choueiri, MD, and Brian Shuch, MD, discuss several studies on the use of belzutifan in patients with renal cancer.
The Uromigos review ASCO GU 2023 data, including triplet vs doublet therapy, the ARASENS trial, and the ZIRCON phase 3 trial.
Brian Shuch, MD, discusses the ZIRCON Phase III imaging study on identification and characterization abilities of TLX250-CDx.
Dr. Brian Rini’s Disclosures
Research Funding to Institution: Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, Exelixis
Consulting: BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, Eisai
Stock: PTC therapeutics
